Newer therapeutic approaches: Spondyloarthritis and uveitis

Rheumatic Disease Clinics of North America

Volumn 32, Issue 1, 2006, Pages 75-90

  Ritchlin, Christopher ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALEFACEPT; ALPHA2A INTERFERON; ANTIMETABOLITE; ANTIPSORIASIS AGENT; AZATHIOPRINE; AZITHROMYCIN; CELECOXIB; CHLORODEOXYADENOSINE; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; EFALIZUMAB; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RAPAMYCIN; RIFAMPICIN; SALAZOSULFAPYRIDINE; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; IDIOPATHIC DISEASE; LIVER TOXICITY; NONHUMAN; OCCUPATIONAL THERAPY; PAIN ASSESSMENT; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; SPONDYLARTHRITIS; SPONDYLOARTHROPATHY; UVEITIS;

ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; PHYSICAL THERAPY MODALITIES; SPONDYLARTHRITIS; TREATMENT OUTCOME; UVEITIS;

EID: 33344475030     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2005.12.003     Document Type: Review

References (66)

1. L. Schlosstein, P.I. Terasaki, and R. Bluestone High association of an HL-A antigen, W27, with ankylosing spondylitis N Engl J Med 288 14 1973 704 706
2. J.D. Reveille, and F.C. Arnett Spondyloarthritis: update on pathogenesis and management Am J Med 118 6 2005 592 603
3. P.S. Helliwell, and W.J. Taylor Classification and diagnostic criteria for psoriatric arthritis Ann Rheum Dis 64 Suppl 2 2005 ii3 ii8
4. D. Gladman Current concepts in psoriatic arthritis Curr Opin Rheumatol 14 4 2002 361 367
5. D. Kane, L. Stafford, and B. Bresnihan A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience Rheumatology (Oxford) 42 12 2003 1460 1468
6. D.D. Gladman, P. Helliwell, and P.J. Mease Assessment of patients with psoriatic arthritis: a review of currently available measures Arthritis Rheum 50 1 2004 24 35
7. D.D. Gladman, V. Strand, and P.J. Mease OMERACT. Psoriatic arthritis workshop: synopsis Ann Rheum Dis 64 Suppl 2 2005 ii115 ii116
8. C.T. Ritchlin, and B.E. Daikh Recent advances in the treatment of the seronegative spondyloarthropathies Curr Rheumatol Rep 3 5 2001 399 403
9. G. Jones, M. Crotty, and P. Brooks Interventions for psoriatic arthritis [update of Cochrane Database Syst Rev 2000;(2)] Cochrane Database of Systematic Reviews 3 2000 CD000212
10. R.F. Willkens, H.J. Williams, and J.R. Ward Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis Arthritis Rheum 27 4 1984 376 381
11. J.P. Kaltwasser, P. Nash, and D. Gladman Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial Arthritis Rheum 50 6 2004 1939 1950
12. R. Zenz, R. Eferl, and L. Kenner Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins Nature 437 7057 2005 369 375
13. C. Ritchlin, S.A. Haas-Smith, and D. Hicks Patterns of cytokine production in psoriatic synovium J Rheumatol 25 8 1998 1544 1552
14. C.L. Danning, G.G. Illei, and C. Hitchon Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis Arthritis Rheum 43 6 2000 1244 1256
15. D. Baeten, E. Kruithof, and F. Van den Bosch Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study Arthritis Rheum 44 1 2001 186 195
16. P.J. Mease, A.J. Kivitz, and F.X. Burch Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 7 2004 2264 2272
17. C. Antoni, G. Krueger, and K. de Vlam Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 Trial Ann Rheum Dis 64 8 2005 150 157
18. P. Mease, D. Gladman, and C. Ritchlin Adalimumab therapy in patients with psoriatic arthritis; 24-week results of a phase III study Arthritis Rheum 52 10 2005 3279 3289
19. P.J. Mease, B.S. Goffe, and J. Metz Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 9227 2000 385 390
20. C.E. Antoni, A. Kavanaugh, and B. Kirkham Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Arthritis Rheum 52 4 2005 1227 1236
21. B. Eibschutz, S.M. Baird, and M.H. Weisman Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report Arthritis Rheum 38 11 1995 1604 1609
22. Mease P. Efalizumab in psoriatic arthritis. Presented at the International Psoriasis Society, 2004. Toronto, Ontario, Canada 2004
23. D. Gladman, P. Mease, and E. Keystone Effficacy of alefacept in combination with methotrexate in the treatment of psoriatic arthritis Ann Rheum Dis 64 111 2005 324
24. J. Braun, M. Bollow, and G. Remlinger Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors Arthritis Rheum 41 1 1998 58 67
25. J. Brandt, J. Listing, and J. Sieper Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis Ann Rheum Dis 63 11 2004 1438 1444
26. M.A. Stone, R.D. Inman, and J.G. Wright Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics Arthritis Rheum 51 3 2004 316 320
27. K.L. Haywood, A.M. Garratt, and K. Dziedzic Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index J Rheumatol 30 4 2003 764 773
28. M. Dougados, B. Dijkmans, and M. Khan Conventional treatments for ankylosing spondylitis Ann Rheum Dis Suppl 3 2002 iii40 iii50
29. H. Dagfinrud, T.K. Kvien, and K.B. Hagen Physiotherapy interventions for ankylosing spondylitis Cochrane Database Syst Rev 4 2004 CD002822
30. A. Wanders, D. Heijde, and R. Landewe Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial Arthritis Rheum 52 6 2005 1756 1765
31. M. Ward Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms? Arthritis Rheum 52 6 2005 1634 1636
32. D.O. Clegg, D.J. Reda, and M.H. Weisman Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study Arthritis Rheum 39 12 1996 2004 2012
33. J. Chen, and C. Lui Methotrexate for ankylosing spondylitis Cochrane Database Syst Rev 3 4 2004 CD004524
34. L. Gonzalez, A. Garcia-Gonzalez, and M. Vasquez-Del Mercado Methotrexate in ankylosing spondylitis J Rheumatol 31 2004 1568 1574
35. K. Redlich, B. Gortz, and S. Hayer Overexpression of tumor necrosis factor causes bilateral sacroiliitis Arthritis Rheum 50 3 2004 1001 1005
36. J. Braun, M. Bollow, and L. Neure Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis Arthritis Rheum 38 4 1995 499 505
37. J.D. Gorman, K.E. Sack, and J.C. Davis Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha N Engl J Med 346 18 2002 1349 1356
38. J. Braun, J. Brandt, and J. Listing Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Arthritis Rheum 48 8 2003 2224 2233
39. J.C. Davis Jr, D. Van Der Heijde, and J. Braun Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis Rheum 48 11 2003 3230 3236
40. A. Calin, B. Dijkmans, and P. Emery Outcomes of a multicenter randomizes clinical trial of etanercept to treat ankylosing spondylitis Ann Rheum Dis 63 2004 1594 1600
41. J. Brandt, J. Listing, and H. Haibel Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis Rheumatology (Oxford) 44 3 2005 342 348 [Erratum in: Rheumatology (Oxford) 2005;44(4):569]
42. D. van der Heijde, B. Dijkmans, and P. Geusens Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 52 2 2005 582 591
43. X. Baraliakos, J. Listing, and J. Brandt Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Arthritis Res Ther 7 3 2005 113 118
44. H. Zeidler, D. Werdier, and A. Klauder Undifferentiated arthritis and spondylarthropathy as a challenge for prospective follow-up Clin Rheumatol 6 Suppl 2 1987 112 120
45. J. Brandt, A. Khariouzov, and J. Listing Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept J Rheumatol 31 3 2004 531 538
46. J. Brandt, H. Haibel, and J. Reddig Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab J Rheumatol 29 1 2002 118 122
47. J. Sieper Disease mechanisms in reactive arthritis Curr Rheumatol Rep 16 2 2004 110 116
48. A. Lauhio, M. Leirisalo-Repo, and J. Lahdevirta Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis Arthritis Rheum 41 1 1991 6 14
49. T.K. Kvien, J.S. Gaston, and T. Bardin Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study Ann Rheum Dis 63 9 2004 1113 1119
50. J. Carter, J. Valeriano, and F. Vasey Doxycycline versus doxycycline plus rifampamycin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis J Rheumatol 31 2004 1973 1980
51. A. Banares, C. Hernandez-Garcia, and B. Fernandez-Gutierrez Eye involvement in the spondyloarthropathies Rheum Dis Clin North Am 24 4 1998 771 784
52. M.J. Lustig, and E.T. Cunningham Jr Use of immunosuppressive agents in uveitis Curr Opin Ophthalmol 14 6 2003 399 412
53. A.D. Dick, P.G. McMenamin, and H. Korner Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina Eur J Immunol 26 5 1996 1018 1025
54. L.N. Santos, C. Marcos, and J. Gallardo Galera Aqueous humor and serum TNF alpha in clinical uveitis Ophthalmic Res 33 2001 251 254
55. C.S. Foster, F. Tufail, and N.K. Waheed Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate Arch Ophthalmol 121 4 2003 437 440
56. J.A. Smith, D.J. Thompson, and S.M. Whitcup A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis Arthritis Rheum 53 1 2005 18 23
57. Y. El-Shabrawi, and J. Hermann Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis Ophthalmology 109 12 2002 2342 2346
58. P.P. Sfikakis, P.H. Kaklamanis, and A. Elezoglou Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease Ann Intern Med 140 5 2004 404 406
59. B. Bodaghi, E. Bui Quoc, and B. Wechsler Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors Ann Rheum Dis 64 6 2005 962 964
60. A.P. Anandarajah, and C.T. Ritchlin Pathogenesis of psoriatic arthritis Curr Opin Rheumatol 16 4 2004 338 343
61. J.R. Abrams, M.G. Lebwohl, and C.A. Guzzo CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris J Clin Invest 103 9 1999 1243 1252
62. J.M. Kremer Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis Rheum Dis Clin North Am 30 2 2004 381 391
63. D.S. Robinson, and A. O'Garra Further checkpoints in Th1 development Immunity 16 6 2002 755 758
64. C.L. Kauffman, N. Aria, and E. Toichi A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis J Invest Dermatol 123 6 2004 1037 1044
65. P.J. Bekker, D.L. Holloway, and A.S. Rasmussen A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 7 2004 1059 1066
66. M. Ziche, S. Donnini, and L. Morbidelli Development of new drugs in angiogenesis Curr Drug Targets 5 5 2004 485 493